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Mycoplasma pneumoniae is one of the most common causes of community-acquired
pneumonia in children and young adults. The incidence of fulminant M. pneumoniae
pneumonia (MPP) is relatively rare despite the high prevalence of M. pneumoniae
infection. This literature review highlights the clinical features of fulminant MPP by
examining the most recent data in epidemiology, clinical presentation, pathogenesis,
and treatment. Fulminant MPP accounts for 0.5–2% of all MPP cases and primarily
affects young adults with no underlying disease. Key clinical findings include a cough,
fever, and dyspnea along with diffuse abnormal findings in radiological examinations.
Levels of inflammatory markers such as white blood cells and C-reactive protein are
elevated, as well as levels of lactate dehydrogenase, IL-18, aspartate transaminase,
and alanine transaminase. The exact pathogenesis of fulminant MPP remains unclear,
but theories include a delayed hypersensitivity reaction to M. pneumoniae and the
contribution of delayed antibiotic administration to disease progression. Treatment
options involve pairing the appropriate anti-mycoplasma agent with a corticosteroid that
will downregulate the hypersensitivity response, and mortality rates are quite low in this
treatment group. Further research is necessary to determine the exact pathogenesis of
severe and fulminant types of MPP.
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INTRODUCTION
Mycoplasma pneumoniae is a common cause of atypical pneumonia often seen in youths and
accounts for 10–15% of cases in Japan (Ishida et al., 2004; Miyashita et al., 2005). M. pneumoniae
pneumonia (MPP) is typically mild and characterized by a persistent dry cough, and sometimes
self-limiting pneumonia cured with no medication, fulminant cases with severe complications
such as respiratory failure, hypoxia, and others have been recognized. Key clinical findings of
fulminant MPP involve respiratory failure with diffuse consolidation or an abnormal interstitial
pattern on a chest radiograph. Material for this review is based on two review articles by
Chan and Welsh (1995) and Izumikawa et al. (2014), along with one case series study by
Miyashita et al. (2007). Table 1 indicates the characters of these three articles. Although
the definition of “fulminant MPP” has not been established, we defined “fulminant MPP”
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TABLE 1 | Two review articles and one case series article.
Reference Type of article Number of cases Unique points
Chan and Welsh, 1995 Review 46 Three category; Non-fatal respiratory failure (n = 26), fatal respiratory failure (n = 13), and fatal without
respiratory failure (n = 7)
Miyashita et al., 2007 Case series 13 13 cases with acute respiratory failure (ARF) and 214 cases without ARF
Izumikawa et al., 2014 Review 52 All cases with respiratory failure
as confirmed MPP cases with respiratory failure or fatal cases
without respiratory failure in this review.
EPIDEMIOLOGY
Approximately 0.5–2% of all MPP cases are the fulminant type,
but the exact frequency of fulminant MPP is unclear (Chan
and Welsh, 1995; Miyashita et al., 2007). Chan and Welsh
(1995) reported that fulminant MPP occurs most frequently
in adolescent males, especially in those with a history of
smoking. Japanese fulminant MPP cases indicated no such
trend (Miyashita et al., 2007; Izumikawa et al., 2014). Our
data revealed that almost 50% of the 52 fulminant MPP cases
occurred in patients aged 20–49 years, and 13.5% occurred
in the elderly (age > 70 years). Only Four cases occurred in
younger patients (age < 20 years). Although several cases of
fulminant MPP were reported among children (Park et al.,
2012), accurate frequency has not been described yet. The
actual mortality rate in fulminant MPP cases is also unknown,
with Chan and Welsh (1995) reporting 3–5% in 1980s and
our review indicating a total of 2 deaths among 52 Japanese
fulminant MPP cases, which is relatively lower (Izumikawa
et al., 2014). Chan reported seven fatal cases of MPP without
respiratory failure and causes of death included pulmonary
thromboembolism, myocarditis, pneumonia, cerebritis, and
psychosis. Extrapulmonary complications may occur, but there
are no recent studies or reviews that address how these
complications affected mortality rates.
CLINICAL AND LABORATORY
FEATURES
The major clinical manifestations of fulminant MPP include a
cough, high fever, and hypoxia along with diffuse abnormal
findings on radiologic examination. In our review, all
52 patients presented with fever (>37.0◦C) on their first
visit to the hospital. A relatively high fever (>38.0◦C)
was observed in 88.5%. Respiratory symptoms such as a
cough and dyspnea were observed upon admission in 97.3
and 83.3% of cases, respectively. The frequency of other
upper respiratory symptoms and sputum production was
lower in fulminant MPP (26.9% had sputum production;
Izumikawa et al., 2014). The average duration from onset
of infection to the development of respiratory failure was
11.2 days (range, 5–21 days; Izumikawa et al., 2014). Chan
and Welsh (1995) and Miyashita et al. (2007) reported
durations of 10–15 and 9.3 days, respectively, from onset
to first administration of appropriate anti-mycoplasma agents.
Both studies reveal a similar timeframe for developing respiratory
failure.
Laboratory findings indicated elevated levels of white blood
cells (WBC) and C-reactive protein (CRP; Miyashita et al., 2007;
Izumikawa et al., 2014). The majority of severe MPP cases
exhibited a moderate inflammation response. Liver dysfunction
was common in fulminant MPP and indicated by elevations of
alanine transaminase (ALT) and aspartate transaminase (AST).
The observed liver dysfunction is not necessarily due to direct
invasion of the liver tissue by M. pneumoniae, and may result
from an indirect immunological response by liver tissue to the
pathogen. Total protein (TP) and lactate dehydrogenase (LDH)
levels are also elevated in fulminant MPP cases (Miyashita
et al., 2007; Izumikawa et al., 2014). However, these abnormal
findings were not specific to fulminant MPP cases and were
present irrespective of disease severity. However, Miyashita et al.
(2007) compared the laboratory findings of severe cases with and
without acute respiratory failure (ARF), and found that WBC
count and levels of CRP, LDH, AST, and ALT were all significantly
higher in the ARF cases. Only TP levels were lower in fulminant
MPP cases with ARF compared to cases without ARF.
RADIOLOGICAL FEATURES
Various radiological findings are observed in fulminant MPP
cases. Miyashita et al. (2007) indicated that bilateral infiltrates
and pleural effusion commonly present in MPP cases with
ARF compared to those without ARF. Izumikawa et al. (2014)
observed a diffuse interstitial pattern (e.g., reticular, nodular,
linear) in 61.5% of cases. A diffuse alveolar pattern with or
without air bronchogram was observed in 25.0% and a mixed
interstitial and alveolar pattern was observed in 13.5%. Pleural
effusion was noted in 13.5%, and these were categorized as
either alveolar or mixed pattern cases. It is unclear what the
differences between these radiological findings indicate, and
observed findings may change throughout the course of the
illness. Interestingly, the radiological findings and severity of
inflammation reflected by inflammation markers indicated that
mixed pattern cases had higher CRP levels compared to those
of interstitial or alveolar pattern cases, though no statistical
differences were observed. These findings indicate a possible
correlation between inflammatory level and radiological findings.
Furthermore, this indicated that radiological findings are closely
related to the body’s immunological response to M. pneumoniae,
and not the local existence of M. pneumoniae itself in the affected
region of the lung.
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PATHOLOGICAL FEATURES
Few case studies describe the pathological findings found through
transbronchial lung biopsy, open lung biopsy, and autopsy from
fulminant MPP (Izumikawa et al., 2014). Acute bronchiolitis was
identified in the early phase of infection, followed by organizing
pneumonia and alveolitis with or without granuloma formation
in the recovery phase. These findings, however, were not acquired
from one specific case. Among fatal MPP cases, very few cases
with diffuse alveolar damage have been reported (Chan and
Welsh, 1995; Miyashita et al., 2007; Izumikawa et al., 2014).
PATHOGENESIS
The literature details how the host’s cell-mediated immunity plays
an important role in the development of typical MPP (Evengard
et al., 1994; Chan and Welsh, 1995; Waites and Talkington,
2004). Factors associated with the virulence of M. pneumoniae
include the following: (i) Toxic byproducts of inflammation can
cause cell damage through direct interaction between human host
cells (e.g., adherence to bronchoepithelial cells, toxin production,
reactive oxygen species, and cytokines). (ii) indirect interaction of
immunological or allergic reaction to M. pneumoniae infection,
and this reaction can influence how the disease progresses
(Fernald et al., 1981; Tanaka et al., 2002).
Although the mechanism and etiology of fulminant MPP
are largely unknown, three possible hypotheses appeared in the
literature: (i) a hyperimmune response that originates in the lung
as a result of repeated childhood M. pneumoniae infections; (ii)
loss of the ability to eradicate M. pneumoniae from the lung
in primary infection resulting in longer-lasting M. pneumoniae
infection in the lung, which may cause a hyperimmune response,
and (iii) overactive innate immune response such as macrophage
activation via heterodimerization of Toll-like receptors two and
six of the bronchoepithelial cells to M. pneumoniae lipoproteins
(Takeuchi et al., 2001). Tanaka et al. (2002) demonstrated that
the levels of serum IL-18, but not of interferon, were higher
in patients with fulminant MPP compared to those in mild
cases, and this was correlated with the number of affected lung
lobes. Recently, Miyashita et al. (2015) supported the notion of
a positive correlation between IL-18 and LDH levels in severe
MPP cases. Thus, an excessive host-cellular response with Th1
cytokines and IL-18 may play a critical role in the development of
fulminant status.
TREATMENT
All previous reports under review indicated that the delayed use
of anti-mycoplasma drugs, such as macrolides (erythromycin,
clarithromycin, and azithromycin), tetracyclines, and quinolones
contributed to the development of fulminant MPP (Chan
and Welsh, 1995; Miyashita et al., 2007; Izumikawa et al.,
2014). β-Lactams and aminoglycosides, both of which have
no potent activity against M. pneumoniae infection, were
used as the initial treatment in 61.5% of cases, and rates
of both inappropriate and no-treatment cases reached 78.8%
(Izumikawa et al., 2014). Corticosteroids are a reasonable
treatment option, especially in fulminant MPP cases that present
with a hyperactive immune response, given that this class of drugs
acts by downregulating the cell-mediated immune response;
numerous reports indicate a positive response (Evengard
et al., 1994; Chan and Welsh, 1995; Takiguchi et al., 2001;
Tsuruta et al., 2002). Currently, there is not enough data
available to establish specific pharmacological guidelines to treat
fulminant MPP. The literature describes a relatively high dose of
methylprednisolone (>500 mg/day) combined with appropriate
anti-mycoplasma agents that effectively improved symptoms
in the majority of patients within 3–5 days of corticosteroid
treatment (Izumikawa et al., 2014). Thirteen cases of severe
or refractory MPP cases required mechanical ventilation, and
nine of these patients received high dose corticosteroids and
anti-mycoplasma agents (Miyashita et al., 2007). Corticosteroid
dosage was gradually tapered within a week in almost all
cases (Izumikawa et al., 2014). The prolonged or inappropriate
usage of corticosteroids may cause excess downregulation of
cell-medicated immunity and result in immunosuppression,
making the individual more susceptible to a more severe
FIGURE 1 | A stepwise algorithm to correlate diagnosis, serum
markers, and initiation of corticosteroid therapy in Mycoplasma
pneumoniae pneumonia (MPP). The permission for usage of this figure was
acquired from both Dr. Naoyuki Miyashita and the Journal of Infection and
Chemotherapy. JRS, Japanese Respiratory Society. M. pneumoniae rapid
antigen tests; Ribotest Mycoplasma (Asahi kasei Pharma Co., Tokyo, Japan)
and PrimeCheck Mycoplasma Antigen (Alfresa Pharma Co., Osaka, Japan).
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M. pneumoniae infection or opportunistic infections such as
those by Pneumocystis, Mycobacterium, or Cytomegalovirus
species. Careful consideration is required when determining
corticosteroid usage.
A recent study recognized that serum LDH levels are
significantly higher in cases of severe MPP compared to the
control group at the initiation of corticosteroid therapy, and may
represent disease severity among adolescents and adults. Lu et al.
(2015) also revealed that serum LDH levels can be used as a
biomarker to predict refractory MPP in children. A serum LDH
level of 302–364 IU/L seems to be an appropriate criterion for
the initiation of corticosteroid therapy in severe or refractory
MPP among adolescents and adults (Miyashita et al., 2015).
Figure 1 indicates the algorithm of corticosteroid administration
in severe and refractory MPP cases (Miyashita et al., 2015).
The Japanese Respiratory Society (JRS) scoring system enables
to differentiate atypical pneumonia from bacterial pneumonia
by positivity of six factors as follows; (i) age < 60 years old,
(ii) no or mild co-morbidity, (iii) paroxysmal cough, (iv) poor
findings from chest physical examination, (v) no expectoration
or no pathogens in rapid diagnostic tests, and (vi) white blood
cell count <10,000/mm3 (Miyashita et al., 2006). In addition,
both of M. pneumoniae antigen, Ribotest Mycoplasma (Asahi
kasei Pharma Co., Tokyo, Japan) and PrimeCheck Mycoplasma
Antigen (Alfresa Pharma Co., Osaka, Japan) were used as rapid
antigen tests for diagnosis of MPP (Miyashita et al., 2015).
CONCLUSION
Mycoplasma pneumoniae pneumonia usually causes a mild
illness, and mortality is quite low. However, severe or fulminant
cases do occur, and these cases require early administration of
corticosteroids, along with administration of appropriate anti-
mycoplasma agents. To date, there are no reports of an increase in
cases of fulminant MPP during the recent outbreak of macrolide-
resistant MPP in Japan, but future research is needed to examine
the correlation between severity of M. pneumoniae infection
and drug resistance, and also to establish clinical guidelines for
management of fulminant MPP.
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